This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: NuPathe

BOSTON (TheStreet) -- Please join me today at 12 p.m. ET for another Biotech Stock Mailbag Live Chat. Bring your biotech stock questions, comments and observations for 90 minutes of lively, interactive chatter.

SBH14 emails to ask, "Adam, do you predict Nupathe's (PATH) migraine patch will receive FDA approval?"

Nupathe's Zelrix is a patch that uses electric current (via a small battery and chip) to actively push the commonly used migraine medicine sumatriptan through the skin and into the patient's bloodstream.

Migraines are an acute, episodic condition, and patients typically seek pain relief as fast as possible, which is why sumatriptan pills (like GlaxoSmithKline's (GSK) Imitrex, now generic) dominate the migraine treatment market. Injectable sumatriptan is also used for even faster pain relief.

A drug patch, even one that actively delivers sumatriptan through the skin like Nupathe's Zelrix, is not going to be quickest or most effective pain reliever. The data from Nupathe's registration studies bear this out. Zelrix's efficacy -- measured by migraines patients reporting either no pain after two hours or reduced pain after two hours -- definitely lags out-of-study comparisons to injectable and oral sumatriptans.

Fortunately for Nupathe, its registration studies compared Zelrix to a placebo, the results of which strongly favored Zelrix. Nupathe Chief Financial Officer Keith Goldan says the FDA asked the company specifically to conduct placebo-controlled studies and did not ask for or require studies against an active comparator for approval purposes.

From a pure efficacy standpoint, Zelrix shouldn't have trouble getting approved. (That's as long as the FDA remains copacetic with placebo-controlled studies.) The approval risk that remains is on the device and safety side. Will the Zelrix patch, with its computer chip and battery, raise enough manufacturing or quality assurance concerns with FDA reviewers to delay approval? It's possible.

The safety data on Zelrix from the clinical studies seem relatively benign, with the exception of an increase in pain and skin irritation where the patch is applied, but again, it's hard to say where FDA balances the risk and benefit here since delaying approval of Zelrix won't necessarily harm migraine sufferers who already have a plethora of treatment options.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.50 +76.37 0.45%
S&P 500 1,992.89 +6.38 0.32%
NASDAQ 4,528.6380 +2.1560 0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs